piroxicam

Summary

Summary: A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily.

Top Publications

  1. Barroso A, Lima V, Guzzo G, Moraes R, Vasconcellos M, Bezerra M, et al. Efficacy and safety of combined piroxicam, dexamethasone, orphenadrine, and cyanocobalamin treatment in mandibular molar surgery. Braz J Med Biol Res. 2006;39:1241-7 pubmed
    ..The aim of the present study was to determine the efficacy and safety of the therapeutic combination of 10 mg piroxicam, 1 mg dexamethasone, 35 mg orphenadrine citrate, and 2...
  2. Iskesen I, Aksoy O, Cerrahoglu M, Sirin H. The effect of piroxicam on the prevention of postoperative retrosternal and pericardial adhesions. Acta Cardiol. 2007;62:559-64 pubmed
    ..The main purpose of our study is to evaluate the effect of an antiinflammatory agent piroxicam on the formation of retrosternal and pericardial adhesions in a rabbit model...
  3. Solanki A, Parikh J, Parikh R. Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level Box-Behnken design. AAPS PharmSciTech. 2007;8:E86 pubmed publisher
    The aim of this study was to investigate the combined influence of 3 independent variables in the preparation of piroxicam proniosomes by the slurry method...
  4. Maghsoodi M, Sadeghpoor F. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique. Drug Dev Ind Pharm. 2010;36:917-25 pubmed publisher
    To improve the dissolution rate of piroxicam (PX), enteric-release microparticles having solid dispersion (SD) structure were prepared in one step...
  5. Hampton D, Hale L. Mast cells are critical for protection against peptic ulcers induced by the NSAID piroxicam. PLoS ONE. 2011;6:e23669 pubmed publisher
    ..mast cell-deficient mice have an extremely high incidence of severe peptic ulceration when exposed to the NSAID piroxicam. This enhanced ulcer susceptibility can be reversed by reconstitution with mast cells...
  6. Wu K, Li J, Wang W, Winstead D. Formation and characterization of solid dispersions of piroxicam and polyvinylpyrrolidone using spray drying and precipitation with compressed antisolvent. J Pharm Sci. 2009;98:2422-31 pubmed publisher
    Solid dispersions of a poorly water-soluble drug piroxicam in polyvinylpyrrolidone (PVP) were prepared by precipitation with compressed antisolvent (PCA) and spray drying techniques...
  7. Abdollahi H, Sororaddin M, Naseri A. Simultaneous spectrofluorometric determination of piroxicam and pyridoxine using generalized rank annihilation method. Anal Sci. 2006;22:263-7 pubmed
    ..rank annihilation method (GRAM) to the analysis of fluorescence excitation-emission matrices of mixtures of piroxicam and pyridoxine is described. The input of GRAM consists of two bilinear data matrices, i.e...
  8. Kalita J, Vajpayee A, Misra U. Comparison of prednisolone with piroxicam in complex regional pain syndrome following stroke: a randomized controlled trial. QJM. 2006;99:89-95 pubmed
    ..To compare the effect of prednisolone with that of piroxicam in patients with CRPSI following stroke. Randomized controlled trial...
  9. Abbaspour A, Mirzajani R. Electrochemical monitoring of piroxicam in different pharmaceutical forms with multi-walled carbon nanotubes paste electrode. J Pharm Biomed Anal. 2007;44:41-8 pubmed
    The electrochemical behavior of piroxicam on a multi-walled carbon nanotubes electrode for the first time was investigated...

More Information

Publications66

  1. Hale L, Gottfried M, Swidsinski A. Piroxicam treatment of IL-10-deficient mice enhances colonic epithelial apoptosis and mucosal exposure to intestinal bacteria. Inflamm Bowel Dis. 2005;11:1060-9 pubmed
    Treatment with the nonsteroidal anti-inflammatory drugs piroxicam or sulindac was recently shown to accelerate the development of colitis in interleukin (IL)-10-deficient (IL-10) mice...
  2. Farshchi A, Ghiasi G. Comparison the analgesic effects of single dose administration of tramadol or piroxicam on postoperative pain after cesarean delivery. Acta Med Iran. 2010;48:148-53 pubmed
    ..randomized, single-dose comparison of the monoaminergic and mu-opioid agonist tramadol, 100 mg (Group T) and piroxicam 20 mg (Group P) given IM alone--single dose in 150 patients who had elective cesarean delivery...
  3. Chang S, Chen L, Chang C, Chu H, Tsai K. Effects of piroxicam-beta-cyclodextrin sachets on abnormal postural sway in patients with chronic low back pain. J Clin Pharm Ther. 2008;33:495-506 pubmed publisher
    The clinical effects of piroxicam-beta-cyclodextrin (PBC) in sachet form have been surveyed in patients with osteoarthritic or acute pain in western countries, but scarcely studied in those with chronic low back pain (LBP), and never ..
  4. Srivastava A, Feng Z, Mishra R, Malhotra R, Kim H, Carrier E. Embryonic stem cells ameliorate piroxicam-induced colitis in IL10-/- KO mice. Biochem Biophys Res Commun. 2007;361:953-9 pubmed
    ..Colitis, induced in IL10-/- KO mice using piroxicam, was associated with the increased levels of IL-12...
  5. Verdina A, Cardillo I, Nebbioso A, Galati R, Menegozzo S, Altucci L, et al. Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability. J Transl Med. 2008;6:27 pubmed publisher
    ..b>Piroxicam, in particular, has been recently shown to exert significant anti-tumoral activity in combination with cisplatin ..
  6. Andreou A, Sibert L, Montes R, Hacpille L, Pfister C, Grise P. [Randomized study comparing piroxicam analgesia and tramadol analgesia during outpatient electromagnetic extracorporeal lithotripsy]. Prog Urol. 2006;16:155-9 pubmed
    ..Group 1 (n-82) received 40 mg of Piroxicam IM, and group 2 (n=89) received 100 mg Tramadol IV Lithotripsy was performed in 2 sequences, T1 and T2, during ..
  7. Chakraborty H, Chakraborty P, Raha S, Mandal P, Sarkar M. Interaction of piroxicam with mitochondrial membrane and cytochrome c. Biochim Biophys Acta. 2007;1768:1138-46 pubmed
    ..is a fundamental requirement for many biological processes. In this work, we present the interaction of piroxicam, a long acting Non-Steroidal Anti-Inflammatory Drug (NSAID) with isolated mitochondria, membrane mimetic systems,..
  8. Palmerini E, Fan K, Yang K, Risio M, Edelmann W, Lipkin M, et al. Piroxicam increases colon tumorigenesis and promotes apoptosis in Mlh1 +/- /Apc1638(N/+) mice. Anticancer Res. 2007;27:3807-12 pubmed
    The present study examines the effect of piroxicam, a non-steroidal anti-inflammatory drug, on tumor development in Mlh1+/- /Apc1638(N/+) mice, in a preclinical model of human colon cancer...
  9. Elmslie R, Glawe P, Dow S. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. J Vet Intern Med. 2008;22:1373-9 pubmed publisher
    ..We hypothesized that continuous treatment with low-dose cyclophosphamide and full-dose piroxicam would delay tumor recurrence in dogs with soft tissue sarcomas (STS)...
  10. Spugnini E, Cardillo I, Verdina A, Crispi S, Saviozzi S, Calogero R, et al. Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res. 2006;12:6133-43 pubmed
    The aim of the present study was to evaluate the effects of piroxicam, a widely used nonsteroidal anti-inflammatory drug, alone and in combination with cisplatin (CDDP), on cell growth of mesothelioma cells...
  11. Tvrdonova M, Dedik L, Mircioiu C, Miklovicova D, Durisova M. Physiologically motivated time-delay model to account for mechanisms underlying enterohepatic circulation of piroxicam in human beings. Basic Clin Pharmacol Toxicol. 2009;104:35-42 pubmed publisher
    ..b>Piroxicam, administered to 24 European, healthy individuals in 20 mg capsules Feldene Pfizer, was used as a model drug...
  12. Lee D, Bae G, Lee M, Choi J, Moon K, Koh J. Nicolau syndrome caused by piroxicam. Int J Dermatol. 2005;44:1069-70 pubmed
  13. Scarpignato C. Piroxicam-?-cyclodextrin: a GI safer piroxicam. Curr Med Chem. 2013;20:2415-37 pubmed
    ..One such drug, piroxicam-?-cyclodextrin (PBC), has been used in Europe for 25 years...
  14. Fernandez S, Chevrier S, Ritter N, Mahler B, Demarne F, Carriere F, et al. In vitro gastrointestinal lipolysis of four formulations of piroxicam and cinnarizine with the self emulsifying excipients Labrasol and Gelucire 44/14. Pharm Res. 2009;26:1901-10 pubmed publisher
    ..The precipitation of piroxicam and cinnarizine formulated in these excipients during the gastrointestinal lipolysis was also studied...
  15. Luksurapan W, Boonhong J. Effects of phonophoresis of piroxicam and ultrasound on symptomatic knee osteoarthritis. Arch Phys Med Rehabil. 2013;94:250-5 pubmed publisher
    To compare the effects of phonophoresis of piroxicam (PhP) and ultrasound therapy (UT) in patients with mild to moderate, symptomatic knee osteoarthritis (OA). A randomized, double-blind, controlled trial...
  16. Mohammad S, Singh V, Wadhwani P, Tayade H, Rathod O. Sublingual piroxicam in the management of postoperative pain after surgical removal of impacted mandibular third molar. Indian J Dent Res. 2012;23:839-40 pubmed publisher
    ..To assess the therapeutic effect of a single dose of 40 mg sublingual piroxicam (study group) vs 150 mg oral diclofenac (50 mg thrice a day) (control group) in patients undergoing surgical ..
  17. Xuan J, Balakrishnan P, Oh D, Yeo W, Park S, Yong C, et al. Rheological characterization and in vivo evaluation of thermosensitive poloxamer-based hydrogel for intramuscular injection of piroxicam. Int J Pharm. 2010;395:317-23 pubmed publisher
    ..gels quickly in the body and allows sustained release of the drug, poloxamer-based hydrogels containing piroxicam as a model drug were prepared with poloxamer, sodium hydroxide and sodium chloride using the cold method...
  18. Alsarra I, Ahmed M, Alanazi F, Eltahir K, AlSheikh A, Neau S. Influence of cyclodextrin complexation with NSAIDs on NSAID/cold stress-induced gastric ulceration in rats. Int J Med Sci. 2010;7:232-9 pubmed
    ..to ameliorate the induction of gastric ulcers by a nonsteroidal anti-inflammatory drug, indomethacin or piroxicam, in rats exposed to restraint and hypothermic stress at 4 degrees C...
  19. Campione E, Diluvio L, Paterno E, Chimenti S. Topical treatment of actinic keratoses with piroxicam 1% gel: a preliminary open-label study utilizing a new clinical score. Am J Clin Dermatol. 2010;11:45-50 pubmed publisher
    ..b>Piroxicam is a nonselective nonsteroidal anti-inflammatory drug that blocks the activity of COX-1 and COX-2...
  20. Obeidat W, Price J. Preparation and evaluation of Eudragit S 100 microspheres as pH-sensitive release preparations for piroxicam and theophylline using the emulsion-solvent evaporation method. J Microencapsul. 2006;23:195-202 pubmed
    Microencapsulation of the anti-inflammatory drug piroxicam and the anti-asthmatic drug theophylline was investigated as a means of controlling drug release and minimizing or eliminating local side effects...
  21. Lust A, Laidmäe I, Palo M, Meos A, Aaltonen J, Veski P, et al. Solid-state dependent dissolution and oral bioavailability of piroxicam in rats. Eur J Pharm Sci. 2013;48:47-54 pubmed publisher
    ..this study was to gain understanding about the effects of different solid-state forms of a poorly water-soluble piroxicam on drug dissolution and oral bioavailability in rats...
  22. Li Y, Rissanen S, Stepniewski M, Cramariuc O, Rog T, Mirza S, et al. Study of interaction between PEG carrier and three relevant drug molecules: piroxicam, paclitaxel, and hematoporphyrin. J Phys Chem B. 2012;116:7334-41 pubmed publisher
    ..poly(ethylene glycol) (PEG) and three drug molecules for which PEG is used to aid delivery: paclitaxel and piroxicam, where PEG is a carrier agent, and hematoporphyrin, where PEG is covalently attached to form a "stealth ..
  23. Piao M, Yang C, Li D, Kim J, Jang K, Yoo B, et al. Preparation and in vivo evaluation of piroxicam-loaded gelatin microcapsule by spray drying technique. Biol Pharm Bull. 2008;31:1284-7 pubmed
    To develop a piroxicam-loaded gelatin microcapsule with enhanced bioavailability, a gelatin microcapsule encapsulated ethanol and piroxicam has been formulated by using gelatin as a water-soluble polymer shell...
  24. Bhattacharya P, Pandey A, Paul S, Patnaik R. Neuroprotective potential of Piroxicam in cerebral ischemia: an in silico evaluation of the hypothesis to explore its therapeutic efficacy by inhibition of aquaporin-4 and acid sensing ion channel1a. Med Hypotheses. 2012;79:352-7 pubmed publisher
    ..Therefore, the target of the present in silico study was to determine the neuroprotective efficacy of Piroxicam, a NSAID in animal model of cerebral ischemia/reperfusion (I/R) injury and efforts were made to analyze its ..
  25. Abdulkarim M, Abdullah G, Chitneni M, Salman I, Ameer O, Yam M, et al. Topical piroxicam in vitro release and in vivo anti-inflammatory and analgesic effects from palm oil esters-based nanocream. Int J Nanomedicine. 2010;5:915-24 pubmed publisher
    ..Drugs of interest are usually those that are problematic when given orally, such as piroxicam, a highly effective anti-inflammatory, anti-pyretic, and analgesic, but with the adverse effect of causing ..
  26. Nishiyori A, Nagakura Y, Ichikawa K. Piroxicam accelerates development of colitis in T-cell receptor alpha chain-deficient mice. Eur J Pharmacol. 2009;615:241-5 pubmed publisher
    ..We have demonstrated that piroxicam induces colitis in non-colitic TCR.alpha-deficient mice, but not wild-type mice, within 14 days...
  27. Prajapati R, Tekade R, Gupta U, Gajbhiye V, Jain N. Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. Mol Pharm. 2009;6:940-50 pubmed publisher
    ..dendrimer-mediated solubilization and formulation development followed by in vitro, in vivo assessment of piroxicam (PXM) nanocomposite. For this, two dendrimer generations (3.0G and 4...
  28. Valizadeh H, Zakeri Milani P, Barzegar Jalali M, Mohammadi G, Danesh Bahreini M, Adibkia K, et al. Preparation and characterization of solid dispersions of piroxicam with hydrophilic carriers. Drug Dev Ind Pharm. 2007;33:45-56 pubmed
    The objective of this study was to improve the dissolution rate of a poor water soluble drug, piroxicam, by solid dispersion technique. Solid dispersions were prepared by three different methods depending on the type of carrier...
  29. Zhang X, Wu D, Lai J, Lu Y, Yin Z, Wu W. Piroxicam/2-hydroxypropyl-beta-cyclodextrin inclusion complex prepared by a new fluid-bed coating technique. J Pharm Sci. 2009;98:665-75 pubmed publisher
    ..The inclusion complex of the model drug piroxicam (PIX) and 2-hydroxypropyl-beta-cyclodextrin (HPCD) in aqueous ethanol solution was sprayed and deposited onto ..
  30. Benetello V, Sakamoto F, Giglio F, Sakai V, Calvo A, Modena K, et al. The selective and non-selective cyclooxygenase inhibitors valdecoxib and piroxicam induce the same postoperative analgesia and control of trismus and swelling after lower third molar removal. Braz J Med Biol Res. 2007;40:1133-40 pubmed
    We compared the clinical efficacy of orally administered valdecoxib and piroxicam for the prevention of pain, trismus and swelling after removal of horizontally and totally intrabony impacted lower third molars...
  31. Costin D, Popa S, Costea C. [Clinical study on the tolerance and efficacy of piroxicam used in cataract surgery, compared with diclofenac and indomethacin]. Rev Med Chir Soc Med Nat Iasi. 2005;109:305-13 pubmed
    The study was done on 75 patients diagnosed with cataract, treated with non-steroidal anti-inflammatory eye drops. This clinical trial recommends piroxicam 0.5% as a reliable alternative of diclofenac 0.1% and indomethacin 0.1%.
  32. Gilhotra R, Gilhotra N, Mishra D. Piroxicam bioadhesive ocular inserts: physicochemical characterization and evaluation in prostaglandin-induced inflammation. Curr Eye Res. 2009;34:1065-73 pubmed publisher
    An attempt has been made in the present research to formulate piroxicam into bioadhesive ocular inserts with an objective to sustain drug release, reduce frequency of dosing, and enhance ocular bioavailability of piroxicam...
  33. Javadzadeh Y, Shariati H, Movahhed Danesh E, Nokhodchi A. Effect of some commercial grades of microcrystalline cellulose on flowability, compressibility, and dissolution profile of piroxicam liquisolid compacts. Drug Dev Ind Pharm. 2009;35:243-51 pubmed
    ..It could be concluded that MCC PH 101 is a suitable carrier for preparing liquisolid systems for having acceptable flowability, friability, hardness, and dissolution profile. ..
  34. Adibkia K, Siahi Shadbad M, Nokhodchi A, Javadzedeh A, Barzegar Jalali M, Barar J, et al. Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. J Drug Target. 2007;15:407-16 pubmed
    To investigate the anti-inflammatory impacts of piroxicam nanosuspension, in the current investigation, piroxicam:Eudragit RS100 nanoformulations were used to control inflammatory symptoms in the rabbits with endotoxin-induced uveitis (..
  35. Nazar M, Khan A, Shah S. Microemulsion system with improved loading of piroxicam: a study of microstructure. AAPS PharmSciTech. 2009;10:1286-94 pubmed publisher
    ..of castor oil/Tween 80/ethanol/phosphate buffer for enhancing the loading capacity of an anti-inflammatory drug piroxicam has been accomplished...
  36. Yin J, Huang Z, Wu B, Shi Y, Cao C, Lu Y. Lornoxicam protects mouse cornea from UVB-induced damage via inhibition of NF-{kappa}B activation. Br J Ophthalmol. 2008;92:562-8 pubmed publisher
    ..The COX inhibitors are protective against UVB-induced skin damage. The aim of this study is to determine the effect of lornoxicam, a potent COX inhibitor, on UVB-induced corneal damage and its mechanism in a mouse model...
  37. Chichlowski M, Westwood G, Abraham S, Hale L. Role of mast cells in inflammatory bowel disease and inflammation-associated colorectal neoplasia in IL-10-deficient mice. PLoS ONE. 2010;5:e12220 pubmed publisher
    ..In addition, although mast cells were previously implicated in progression of sporadic colon cancers, mast cells did not affect the incidence or severity of colonic neoplasia in this inflammation-associated model. ..
  38. Mat Hadzir N, Basri M, Abdul Rahman M, Salleh A, Raja Abdul Rahman R, Basri H. Phase behaviour and formation of fatty acid esters nanoemulsions containing piroxicam. AAPS PharmSciTech. 2013;14:456-63 pubmed publisher
    ..construct pseudo-ternary phase diagrams for oleyl laurate, oleyl stearate and oleyl oleate with surfactants and piroxicam. Then, the preparation and optimization study via 'One-At-A-Time Approach' were carried out to determine the ..
  39. Richy F, Scarpignato C, Lanas A, Reginster J. Efficacy and safety of piroxicam revisited. A global meta-analysis of randomised clinical trials. Pharmacol Res. 2009;60:254-63 pubmed publisher
    ..To better understand the efficacy and safety profile of piroxicam, a widely used NSAID, a meta-analysis of comparative RCTs was carried out according to the QUOROM guidance...
  40. Perini J, Suarez Kurtz G. Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of piroxicam. Clin Pharmacol Ther. 2006;80:549-51 pubmed
  41. Knottenbelt C, Chambers G, Gault E, Argyle D. The in vitro effects of piroxicam and meloxicam on canine cell lines. J Small Anim Pract. 2006;47:14-20 pubmed
    To analyse the direct antiproliferative effects of both piroxicam and meloxicam at a variety of concentrations on a series of canine cancer cell lines and the mechanism of cell death...
  42. Royals S, Farese J, Milner R, Lee Ambrose L, van Gilder J. Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res. 2005;66:1961-7 pubmed
    To determine whether exposure of canine osteosarcoma cells to deracoxib or piroxicam results in decreased viability, whether the cytotoxic effects of deracoxib and piroxicam involve induction of apoptosis, and whether deracoxib is a more ..
  43. Perini J, Vianna Jorge R, Brogliato A, Suarez Kurtz G. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clin Pharmacol Ther. 2005;78:362-9 pubmed
    ..CYP) 2C9 polymorphisms on the pharmacokinetics and pharmacodynamics of the nonsteroidal anti-inflammatory drug piroxicam. Thirty-five healthy subjects with CYP2C9 genotypes *1/*1 (n=17), *1/*2 (n=9), and *1/*3 (n=9) received a single ..
  44. Spugnini E, Crispi S, Scarabello A, Caruso G, Citro G, Baldi A. Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations. J Exp Clin Cancer Res. 2008;27:6 pubmed publisher
    ..Aim of this study was the preclinical evaluation of the combination of piroxicam with platinum-based intracavitary chemotherapy in pets...
  45. Paaver U, Lust A, Mirza S, Rantanen J, Veski P, Heinämäki J, et al. Insight into the solubility and dissolution behavior of piroxicam anhydrate and monohydrate forms. Int J Pharm. 2012;431:111-9 pubmed publisher
    ..of surfactant sodium lauryl sulphate (SLS) on the solubility and dissolution rate of two solid-state forms of piroxicam (PRX), anhydrate (PRXAH) and monohydrate (PRXMH), and (2) to quantitatively assess the solid-phase ..
  46. Sonzogni Desautels K, Knapp D, Sartin E, Dore M. Effect of cyclooxygenase inhibitors in a xenograft model of canine mammary tumours. Vet Comp Oncol. 2011;9:161-71 pubmed publisher
    ..Our goal was to compare the effect of a selective inhibitor of COX-2, deracoxib, and a COX-1 and -2 inhibitor, piroxicam, on the growth of canine mammary tumours in a murine model. CMT-9 was used to induce xenografts in nude mice...
  47. A sasutjarit R, Sirivat A, Vayumhasuwan P. Viscoelastic properties of Carbopol 940 gels and their relationships to piroxicam diffusion coefficients in gel bases. Pharm Res. 2005;22:2134-40 pubmed
    This study was conducted to determine the effect of formula compositions on viscoelastic properties of piroxicam gels using Carbopol 940 as a gelling agent and to determine the relationships between viscoelastic properties of Carbopol ..
  48. Attama A. Polyelectrolyte complexes of Eudragit l30 d-55 and gelatin: antinociceptive activity of entrapped piroxicam. Drug Deliv. 2007;14:155-62 pubmed
    ..The pharmacodynamic effects of piroxicam entrapped in the complexes were determined using healthy rats...
  49. Park E, Cui Y, Yun B, Ko I, Chi S. Transdermal delivery of piroxicam using microemulsions. Arch Pharm Res. 2005;28:243-8 pubmed
    To improve the skin permeability of piroxicam, a new oil-in-water microemulsion containing 0.5% piroxicam was developed...
  50. Jug M, Bećirević Laćan M. Multicomponent complexes of piroxicam with cyclodextrins and hydroxypropyl methylcellulose. Drug Dev Ind Pharm. 2004;30:1051-60 pubmed
    ..of the study was to investigate the effect of hydroxypropyl methylcellulose (HPMC) on the complexation of piroxicam (PX) with beta-cyclodextrin (beta-CD) and dimethyl-beta-cyclodextrin (DM-beta-CD) in solution and in the solid ..
  51. Vartiainen N, Huang C, Salminen A, Goldsteins G, Chan P, Koistinaho J. Piroxicam and NS-398 rescue neurones from hypoxia/reoxygenation damage by a mechanism independent of cyclo-oxygenase inhibition. J Neurochem. 2001;76:480-9 pubmed
    We studied whether NS-398, a selective cyclo-oxygenase-2 (COX-2) enzyme inhibitor, and piroxicam, an inhibitor of COX-2 and the constitutively expressed COX-1, protect neurones against hypoxia/reoxygenation injury...
  52. Mohammed S, Craig B, Mutsaers A, Glickman N, Snyder P, DeGortari A, et al. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mol Cancer Ther. 2003;2:183-8 pubmed
    ..of this study were: (a) to determine the antitumor activity and toxicity of a cyclooxygenase inhibitor (piroxicam) combined with cisplatin chemotherapy in dogs with naturally-occurring, invasive transitional cell carcinoma (..
  53. Okuyama H, Ikeda Y, Kasai S, Imamori K, Takayama K, Nagai T. Influence of non-ionic surfactants, pH and propylene glycol on percutaneous absorption of piroxicam from cataplasm. Int J Pharm. 1999;186:141-8 pubmed
    ..polyoxyethylene (POE) non-ionic surfactants and addition of propylene glycol (PG) on percutaneous absorption of piroxicam (Px) from cataplasm was investigated in guinea-pig in vivo...
  54. Boria P, Murry D, Bennett P, Glickman N, Snyder P, Merkel B, et al. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. J Am Vet Med Assoc. 2004;224:388-94 pubmed
    To determine the maximum tolerated dose (MTD) of cisplatin administered with piroxicam, the antitumor activity and toxicity of cisplatin combined with piroxicam in dogs with oral malignant melanoma (OMM) and oral squamous cell carcinoma (..
  55. Ding H, Han C, Gibson D Ambrosio R, Steele V, D Ambrosio S. Piroxicam selectively inhibits the growth of premalignant and malignant human oral cell lines by limiting their progression through the S phase and reducing the levels of cyclins and AP-1. Int J Cancer. 2003;107:830-6 pubmed
    ..In our study, we found that piroxicam inhibited cell growth in premalignant and malignant, but not normal, human oral epithelial cell lines in a ..
  56. Curdy C, Kalia Y, Naik A, Guy R. Piroxicam delivery into human stratum corneum in vivo: iontophoresis versus passive diffusion. J Control Release. 2001;76:73-9 pubmed
    A nonsteroidal anti-inflammatory drug, piroxicam, was administered from a commercially available gel to human volunteers both passively and under the application of an iontophoretic current...
  57. Schmidt B, Glickman N, Denicola D, de Gortari A, Knapp D. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J Am Vet Med Assoc. 2001;218:1783-6 pubmed
    To evaluate the use of piroxicam for the treatment of oral squamous cell carcinoma in dogs. Prospective case series. 17 dogs with measurable oral squamous cell carcinoma. Dogs were treated with piroxicam at a dosage of 0.3 mg/kg (0...